Evidence map›Paper›PMID 42689447›Full record

ArticleJournal of peptide science : an official publication of the European Peptide Society2026

Novel Peptide-Triazole Conjugates: Strategic Synthesis, Antimicrobial Properties, and Molecular Docking Study.

Jigar Bhavsar, Sunil Tivari, Swati Swornaprava Pati, Pooja Bhanderi, Bhaveshkumar Makwana, Ranjan Khunt, Neeraj Kumar, Vivek Kumar Chaturvedi, Ruby Singh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of peptide science : an official publication of the European Peptide Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jigar BhavsarDepartment of Chemistry, Jaipur National University, Jaipur, Rajasthan, India.ORCID https://orcid.org/0009-0006-7933-5971
Sunil TivariDepartment of Chemistry, Saurashtra University, Rajkot, Gujarat, India.ORCID https://orcid.org/0000-0002-9549-7122
Swati Swornaprava PatiCentral University of Rajasthan, Rajasthan, India.
Pooja BhanderiDepartment of Chemistry, Saurashtra University, Rajkot, Gujarat, India.
Bhaveshkumar MakwanaDepartment of Chemistry, Gujarat Arts & Science College, Ahmedabad, Gujarat, India.ORCID https://orcid.org/0009-0006-5839-6513
Ranjan KhuntDepartment of Chemistry, Saurashtra University, Rajkot, Gujarat, India.ORCID https://orcid.org/0000-0001-8155-5320
Neeraj KumarMankind Research Center, Gurugram, Haryana, India.ORCID https://orcid.org/0009-0007-4243-1692
Vivek Kumar ChaturvediMankind Research Center, Gurugram, Haryana, India.
Ruby SinghDepartment of Chemistry, Jaipur National University, Jaipur, Rajasthan, India.ORCID https://orcid.org/0000-0002-4591-4100

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rising incidence of multidrug-resistant (MDR) bacteria demands the creation of innovative antimicrobial agents characterized by enhanced stability and efficacy. In this study, a series of peptide-heterocycle conjugates was systematically designed and synthesized using solid-phase peptide synthesis (SPPS), featuring octapeptide-triazole conjugates modified with a triazole-based moiety. Non-proteinogenic amino acids, specifically 2-aminoisobutyric acid (Aib) and 2-naphthylalanine (2-Nal), were used to add structural diversity. SPPS is a relatively easy way to synthesize these compounds, which ensures accuracy in the sequence. The synthesized peptides were subjected to an antimicrobial activity assessment following a molecular docking study. In comparison to the standard drug, compound 7e exhibited promising antibacterial activity against E. coli, with the MIC value of 12 μg/mL, whereas compound 7a showed enhanced activity against P. aeruginosa with the MIC value of 12 μg/mL. Compound 7a exhibited better to moderate antifungal activity against C. albicans, with the MIC values of 25 μg/mL.

Indexed as

Anti-Bacterial AgentsAntifungal AgentsAntimicrobial PeptidesMolecular Docking SimulationTriazolesAminoisobutyric AcidsCandida albicansEscherichia coliMicrobial Sensitivity TestsMolecular StructurePseudomonas aeruginosaSolid-Phase Synthesis TechniquesStructure-Activity Relationship2-aminoisobutyric acidAminoisobutyric AcidsAnti-Bacterial AgentsAntifungal AgentsAntimicrobial PeptidesTriazolesantimicrobial peptidesbiological evaluationdocking studiesnon‐proteinogenic amino acidspeptide–triazole hybridssolid‐phase synthesis method

Identifiers

PMID42689447
PMCPMC13539548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.